Navigation Links
Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results
Date:11/9/2009

trategies to address its markets successfully; the early stage of market development for certain of the Company's products; the risk of adverse events and product liability claims; risks related to the use and protection of intellectual property; expenses and uncertainties relating to litigation; technical innovations that could render products marketed or under development by the Company obsolete; competition; the risks of conducting business internationally, including the effect of exchange rate fluctuations on those operations; financing risks, including the Company's obligation to meet financial covenants and payment obligations under the Company's financing arrangements and leases; and the Company's ability to attract and retain qualified personnel.

The risks included above are not exhaustive. Other factors that could adversely affect the Company's business and prospects are described in the Company's filings with the Securities and Exchange Commission. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in the Company's expectations or any change in events, conditions or circumstances on which any such statement is based.



    Contact:  Deborah R. Gordon
              Vice President, Investor Relations
              Hologic, Inc.
              (781) 999-7716



                                      HOLOGIC, INC.
                          CONDENSED CONSOLIDATED BALANCE SHEETS
                                       (Unaudited)
                                      (In thousands)

                                         ASSETS

                                            September 26,     September 27,
                                                    2009              2008
                                                    ----              ----

     CURRENT ASSETS:
     Cash and cash equivalents                   $293,186          $95,
'/>"/>
SOURCE Hologic, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28

Related medicine technology :

1. Three Year Analysis of Treatment Efficacy, Cosmesis, and Toxicity Support use of the Hologic Mammosite Radiation Therapy System
2. ALS Therapy Development Institute Partners with Clinical Centers to Establish Pathological Mechanisms of Lou Gehrigs Disease
3. Hologic Releases the Results of the Cervista(TM) HPV Clinical Trials
4. Paclitaxel Poliglumex (OPAXIO(TM)) Added to Cisplatin and Radiation Produces 45% Pathologic Complete Remissions in Patients With Esophageal Cancer
5. Clinical and Histopathological Results Using Pollogens TriPollar(TM) Radio Frequency Technology Published in the June Issue of the Journal of Cosmetic and Laser Therapy
6. Hologic Receives CE Marking for the ThinPrep(R) Integrated Imager
7. OPAXIO Produces High Rates of Pathologic Complete Remission in Patients with Advanced Esophageal Cancer; Study Paves Way for Potential Registration Trial as Radiation Sensitizer
8. Hologic Expands Healthcare Investment in Asia
9. Hologic to Host Investor Reception at RSNA 2009
10. Hologic to Present at Citis 2009 Sixth Annual Small/Mid Cap Conference
11. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... -- According to the new research ... Reagent, Primer, Probe, Custom Oligos), End-User (Research, Pharmaceutical ... NGS, DNA, RNAi) - Global Forecast to 2019" ... is expected to reach $1,712.1 Million by 2019 ... CAGR of 9.8% from 2014 to 2019.. ...
(Date:8/29/2014)... YORK, Pa. , Aug. 29, 2014  Unilife ...  ASX: UNS) announced today that it intends to release ... and year ended June 30, 2014 after market trading ... Management has scheduled a conference call for 4:30 p.m. ... 10, 2014 at 6:30 a.m. AEST), to review the Company,s ...
(Date:8/29/2014)... Aug. 29, 2014 Research and Markets ... Multiple Sclerosis Drugs Market 2014-2018" report to their ... inflammatory medical condition that results in demyelination, axonal transection, ... an abnormal response by the immune system, which targets ... a potentially debilitating disease in which the damage of ...
Breaking Medicine Technology:Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 3Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 4Unilife Corporation to Announce Financial Results for Fiscal Year 2014 Fourth Quarter and Year End on Tuesday, September 9, 2014 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 3
... Diagnostics (SIX: RO, ROG; OTCQX: RHHBY) announced today that ... for cardiac biomarker testing on the cobas ® ... labs with medium testing volumes. With a 9-minute duration, ... tests currently available on an integrated platform and enable ...
... and MYSTIC, Conn., Sept. 16 Amarin Corporation plc (Nasdaq: ... Financial Officer, is scheduled to present on Amarin,s behalf at ... 2010 at 12:30 pm. This conference will be held at ... Stewart, recently appointed as President and Chief Executive Officer, will ...
Cached Medicine Technology:Roche Diagnostics Introduces Full Line of 9-Minute STAT Assays for Cardiac Biomarker Testing on cobas 6000 Analyzer Series 2Roche Diagnostics Introduces Full Line of 9-Minute STAT Assays for Cardiac Biomarker Testing on cobas 6000 Analyzer Series 3Amarin to Present at UBS Life Sciences Conference 2
(Date:8/29/2014)... As reported by WKMS.com in the article ... municipal court drug has come up with a new strategy ... as the presiding judge in a Southeastern Ohio municipal court ... a medicated treatment option that can literally prevent them from ... Vivitrol, which blocks receptors in the brain that would normally ...
(Date:8/29/2014)... by the Frederick News Post in the article Run For ... the Frederick County Drug Treatment Court has found a new way ... graduate, Korey Shorb, put together a race called Run For Recovery ... donate the proceeds of the event to the program he graduated ... graduated in 2008, admitted that he would probably be in jail ...
(Date:8/29/2014)... Healthpointe is proud to welcome to ... will be practicing out of Healthpointe’s newest office directly ... Healthpointe’s orthopedic team, Dr. Rodas is board-certified ... in occupational medicine. , Among Dr. Rodas’ many ... of Raytheon, the world-class defense and aerospace company. Additionally, ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 Healthpointe ... Chapman University Physical Therapy students via Clinical Rotations. ... University will be shadowing Healthpointe providers and specialists ... them to develop clinical experience and learn professional ... students will gain insight into several patient care ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 Pursuing its ... is set to unveil a stunning new design that ... company figures, the highly notable surrogacy platform has witnessed ... With over 13,000 visitors a month, the FindSurrogateMother.com community ... working toward one common goal — the precious gift ...
Breaking Medicine News(10 mins):Health News:Ohio Judge Pushes for Addiction Recovery Tool 2Health News:Ohio Judge Pushes for Addiction Recovery Tool 3Health News:Drug Court Grad Brings More Life to Drug Court Program 2Health News:Drug Court Grad Brings More Life to Drug Court Program 3Health News:Dr. Anthony G. Rodas Joins Healthpointe Team at LAX Office 2Health News:Healthpointe is Now Offering Clinical Rotations for Chapman University Physical Therapy Students 2Health News:FindSurrogateMother.com Set to Unveil Stunning New Design as Member Sign-ups Increase by 42% since January 2Health News:FindSurrogateMother.com Set to Unveil Stunning New Design as Member Sign-ups Increase by 42% since January 3
... Executive says that almost 25 percent of cancer patients in ... the targeted time of two months. //The current data is ... ,The report said that just about 75 percent of all ... fell to 60 percent for bowel cancer patients and those ...
... Gripp and his team from DuPont Hospital studied genetic ... scientists found that the gene mutation occured in germline ... of the parents of the affected patients. The researchers ... Interscience. The researchers identified mutations in codon 12 or ...
... can be triggered by exposure to endotoxins in the ... Critical Care Medicine study. Humidifiers, pests, dust, pets, and ... according to the University of Iowa’s Dr. Peter S. ... homes selected to represent the demographic characteristics of the ...
... Centre International de Recherches Médicales de Franceville has identified ... of infection by the deadly Ebola virus // . ... are eaten in Central Africa by local Congolese and ... the infection is contracted through the eating habits of ...
... hope regarding the DNA vaccine trials conducted against the ... have already been completed among 40 HIV- negative // ... in the area of vaccine biology. It involves direct ... antigens into the human body. These vaccines precipitate an ...
... women who have had vaginal deliveries prior to their menopause ... their sisters who have never given birth // . In ... to their counterparts. ,Over 10 million people worldwide ... the other. It is a major health issue that ...
Cached Medicine News:Health News:DNA Vaccine Trials Against HIV Virus In Sweden Nurture Hope 2Health News:Urinary Stress Incontinence Not Related To Childbirth 2
... TOX/See™ is a 1-step, hand-held, point-of-care device for ... in human urine. The TOX/See device can ... abused drugs in 3 to 8 minutes and ... TOX/See cassette is individually packaged to maximize convenience ...
... point-of-care device for the qualitative detection of drug ... TOX/See device can detect up to nine of ... 8 minutes and requires only a few drops ... to maximize convenience and ease of use. TOX/See ...
... device for the qualitative detection of drug or ... device can detect up to nine of the ... minutes and requires only a few drops of ... maximize convenience and ease of use. TOX/See features ...
... TOX/See™ is a 1-step, hand-held, point-of-care device for ... in human urine. The TOX/See device can ... abused drugs in 3 to 8 minutes and ... TOX/See cassette is individually packaged to maximize convenience ...
Medicine Products: